With the integration of Impax Laboratories Inc. now complete, one of the first orders of business for Amneal Pharmaceuticals Inc. was to initiate a phase III trial of IPX-203, an oral sustained-release version of carbidopa-levodopa (CD-LD) in individuals with advanced Parkinson's disease (PD). The move, combined with Amneal's disclosure of a biosimilars partnership with Mabxience SL, on the day Amneal's shares began to trade on the New York Stock Exchange as AMRX, signaled the Bridgewater, N.J.-based company's intention to move beyond generics and build a pipeline that is at once profitable and "more affordable and accessible" for patients.